PAVmed Subsidiary Lucid Diagnostics Announces Commercial Launch of EsoGuard Esophageal DNA Test
December 19, 2019 09:30 ET
|
PAVmed Inc.
First commercially available DNA test designed to facilitate the diagnosis of Barrett’s Esophagus and related precursors to highly lethal form of esophageal cancer First patients to undergo testing...
PAVmed Provides Update on CarpX™ Clinical Safety Study
December 13, 2019 09:30 ET
|
PAVmed Inc.
NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on...
PAVmed Reports Third Quarter 2019 Financial Results and Provides Business Update
November 21, 2019 16:00 ET
|
PAVmed Inc.
Conference call to be held on November 21, 2019 at 4:30 p.m. Eastern time NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly...
PAVmed Partners with Laser Technology Pioneer Dr. Jacob Wong to Develop and Commercialize Non-Invasive Laser-based Diagnostic Products
November 14, 2019 09:30 ET
|
PAVmed Inc.
Secures exclusive worldwide license for Nondispersive Infrared (NDIR) laser technology Launches joint development program for NDIR laser-based diagnostic products to measure glucose, electrolytes...
PAVmed’s PortIO™ Intraosseous Infusion System Achieves Multiple Milestones
November 07, 2019 09:30 ET
|
PAVmed Inc.
Unprecedented six-month maintenance-free implant duration achieved FDA pre-submission meeting date supporting de novo application secured Broad method and device patents granted by USPTO NEW YORK,...
PAVmed to Hold Business Update Conference Call on November 21, 2019
November 06, 2019 09:30 ET
|
PAVmed Inc.
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization
November 05, 2019 07:00 ET
|
PAVmed Inc.
Extends cash runway to support multiple milestones including commercialization of two lead products NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or...
PAVmed Reports Second Quarter 2019 Financial Results and Provides Business Update
September 05, 2019 09:30 ET
|
PAVmed Inc.
Conference call to be held on September 5, 2019 at 4:30 p.m. Eastern time NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly...
USPTO Grants PAVmed Patent Covering its CarpX™ Device
August 21, 2019 09:30 ET
|
PAVmed Inc.
NEW YORK, Aug. 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the U.S....
PAVmed Successfully Completes Clinical Safety Study Procedures for CarpX™ 510(k) Re-submission
August 15, 2019 09:30 ET
|
PAVmed Inc.
All 20 patients underwent successful CarpX procedures while passing primary effectiveness endpoint, with all follow-up patients to date passing primary safety endpoint NEW YORK, Aug. 15, 2019 ...